HealthInvest Partners AB lowered its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 15.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 412,588 shares of the company’s stock after selling 77,743 shares during the period. Anika Therapeutics makes up 10.1% of HealthInvest Partners AB’s portfolio, making the stock its largest position. HealthInvest Partners AB’s holdings in Anika Therapeutics were worth $22,135,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Anika Therapeutics by 165.8% in the first quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock worth $13,434,000 after buying an additional 187,400 shares during the period. Bogle Investment Management L P DE boosted its stake in shares of Anika Therapeutics by 118.1% in the first quarter. Bogle Investment Management L P DE now owns 110,969 shares of the company’s stock worth $4,962,000 after buying an additional 60,087 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Anika Therapeutics by 308.7% in the first quarter. Fisher Asset Management LLC now owns 57,719 shares of the company’s stock worth $2,792,000 after buying an additional 43,595 shares during the period. Panagora Asset Management Inc. boosted its stake in shares of Anika Therapeutics by 965.7% in the first quarter. Panagora Asset Management Inc. now owns 30,234 shares of the company’s stock worth $1,352,000 after buying an additional 27,397 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Anika Therapeutics by 17.4% in the first quarter. Acadian Asset Management LLC now owns 173,771 shares of the company’s stock worth $7,771,000 after buying an additional 25,727 shares during the period. 77.85% of the stock is currently owned by institutional investors and hedge funds.

Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 0.71% during trading on Wednesday, hitting $47.93. 142,791 shares of the stock were exchanged. The stock has a market cap of $708.26 million, a P/E ratio of 20.92 and a beta of 1.50. The stock has a 50 day moving average of $48.18 and a 200-day moving average of $47.84. Anika Therapeutics Inc. has a 52 week low of $30.93 and a 52 week high of $54.96.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Anika Therapeutics had a net margin of 33.77% and a return on equity of 17.24%. The company earned $26.60 million during the quarter, compared to the consensus estimate of $24.75 million. During the same period in the previous year, the firm posted $0.51 EPS. The firm’s revenue was up 16.2% compared to the same quarter last year. Equities analysts expect that Anika Therapeutics Inc. will post $2.00 EPS for the current fiscal year.

Separately, Zacks Investment Research raised shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price target on the stock in a research report on Monday, August 1st.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.